478 related articles for article (PubMed ID: 26943983)
1. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
[TBL] [Abstract][Full Text] [Related]
2. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
[TBL] [Abstract][Full Text] [Related]
3. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).
Mihaylova B; Schlackow I; Herrington W; Lozano-Kühne J; Kent S; Emberson J; Reith C; Haynes R; Cass A; Craig J; Gray A; Collins R; Landray MJ; Baigent C;
Am J Kidney Dis; 2016 Apr; 67(4):576-84. PubMed ID: 26597925
[TBL] [Abstract][Full Text] [Related]
7. Association between intensity of statin therapy and mortality in persons with chronic kidney disease.
Walther CP; Richardson PA; Virani SS; Winkelmayer WC; Navaneethan SD
Nephrol Dial Transplant; 2020 Feb; 35(2):312-319. PubMed ID: 30053252
[TBL] [Abstract][Full Text] [Related]
8. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M;
Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Katsiki N; Mikhailidis DP; Banach M
Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
[No Abstract] [Full Text] [Related]
10. LDL-cholesterol lowering and renal outcomes.
Waters DD
Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
[TBL] [Abstract][Full Text] [Related]
11. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
Last AR; Ference JD; Menzel ER
Am Fam Physician; 2017 Jan; 95(2):78-87. PubMed ID: 28084704
[TBL] [Abstract][Full Text] [Related]
12. On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - The multi-center T-SPARCLE registry study.
Ho LT; Lin FJ; Tseng WK; Yin WH; Wu YW; Li YH; Yeh HI; Chen JW; Wu CC;
J Formos Med Assoc; 2018 Sep; 117(9):814-824. PubMed ID: 29945742
[TBL] [Abstract][Full Text] [Related]
13. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
[TBL] [Abstract][Full Text] [Related]
14. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD.
Sarnak MJ; Bloom R; Muntner P; Rahman M; Saland JM; Wilson PW; Fried L
Am J Kidney Dis; 2015 Mar; 65(3):354-66. PubMed ID: 25465166
[TBL] [Abstract][Full Text] [Related]
15. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Lin YC; Lai TS; Wu HY; Chou YH; Chiang WC; Lin SL; Chen YM; Chu TS; Tu YK
Clin Pharmacol Ther; 2020 Oct; 108(4):833-843. PubMed ID: 32320058
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
[TBL] [Abstract][Full Text] [Related]
18. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
[TBL] [Abstract][Full Text] [Related]
19. Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.
Heine GH; Rogacev KS; Weingärtner O; Marsche G
Semin Dial; 2017 Sep; 30(5):390-394. PubMed ID: 28628255
[TBL] [Abstract][Full Text] [Related]
20. Danish guidelines for lipid-lowering treatment in patients with chronic renal failure.
Dieperink H; Christensen JH; Feldt-Rasmussen B; Schmidt EB; ;
Dan Med J; 2014 Apr; 61(4):C4843. PubMed ID: 24814603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
